Citations

Showing 10 of 108104 citations.

Efficacy of Lopinavir–Ritonavir Combination Therapy for the Treatment of Hospitalized COVID-19 Patients: A Meta-Analysis
Deng, Jiawen , Zhou, Fangwen , Hou, Wenteng , Heybati, Kiyan , Ali, Saif , Chang, Oswin , Silver, Zachary , Dhivagaran, Thanansayan , Ramaraju, Harikrishnaa Ba , Wong, Chi Yi , Zuo, Qi , Lapshina, Elizabeth , Mellett, Madeline , Zuo, Qi Kang , Deng, J , Zhou, F

Mayo Clinic

Future Virology | January 31, 2022 | Volume: 17 | Issue: 3 | Pages: 169-189

10.2217/fvl-2021-0066 | PMID 35145560 Get It

Horticultural Therapy: An Ancient Integrative Approach for Modern Times
Dabrh, Abd Moain Abu , Meore, Anne, Wilson, Edward W., Abu Dabrh, Abd Moain , Perlman, Adam

Mayo Clinic

Journal of Integrative and Complementary Medicine | January 31, 2022 | Volume: 28 | Issue: 4 | Pages: 290-293

10.1089/jicm.2021.0174 | PMID 35100045 Get It

Atrial Fibrillation and Dementia: A Report From the AF-SCREEN International Collaboration
Rivard, Léna , Friberg, Leif , Conen, David , Healey, Jeff S. , Berge, Trygve , Boriani, Giuseppe , Brandes, Axel , Calkins, Hugh , Camm, A. John , Espuny, Josep Lluis Clua , Collins, Ronan, Connolly, Stuart, Dagres, Nikolaos , Elkind, Mitchell S.V. , Engdahl, Johan, Field, Thalia S. , Glotzer, Taya V., Hankey, Graeme J. , Hills, Mellanie True , Johnson, Linda S.B. , Joung, Boyoung, Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Montaner, Joan , Rienstra, Michiel , Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Stavrakis, Stavros , Gelder, Isabelle C. Van, Wang, Ji‐Guang , Freedman, Ben , Joung, Boyoung , Healey, Jeffrey S , Chen, Lin Y , Lluis Clua Espuny, Josep , Dagres, Nikolaos , Elkind, Mitchell S V , Field, Thalia S , Gersh, Bernard J , Hankey, Graeme J , Harbison, Joseph A , Haeusler, Karl G , True Hills, Mellanie , Johnson, Linda S B , Khairy, Paul , Kirchhof, Paulus , Lip, Gregory Y H , Montaner, Joan , Ntaios, George , Quinn, Terence J , Rienstra, Michiel , Schnabel, Renate B , Stavrakis, Stavros , Themistoclakis, Sakis , Wang, Ji-Guang , Freedman, Ben , Boriani, Giuseppe , Joung, Boyoung , Brandes, Axel , Rivard, Lena , Friberg, Leif , Conen, David , Berge, Trygve , Calkins, Hugh , Camm, Alan John , Collins, Ronan, Connolly, Stuart, Engdahl, Johan, Glotzer, Taya V., Krieger, Derk, Løchen, Maja-Lisa, Madhavan, Malini, Mairesse, Georges H., Rosenqvist, Mårten, Sandhu, Roopinder K., Smyth, Breda, Gelder, Isabelle C. Van

Mayo Clinic

Circulation | January 31, 2022 | Volume: 145 | Issue: 5 | Pages: 392-409

10.1161/circulationaha.121.055018 | PMID 35100023 Get It

Growing evidence suggests a consistent association between atrial fibrillation (AF) and cognitive impairment and dementia that is independent of clinical stroke. This report from the AF-SCREEN International Collaboration summarizes the evidence linking AF to cognitive impairment and dementia. It provides guidance on the investigation and management of dementia in patients with AF on the basis of best available evidence. The document also addresses suspected pathophysiologic mechanisms and identifies knowledge gaps for future research. Whereas AF and dementia share numerous risk factors, the association appears to be independent of these variables. Nevertheless, the evidence remains inconclusive regarding a direct causal effect. Several pathophysiologic mechanisms have been proposed, some of which are potentially amenable to early intervention, including cerebral microinfarction, AF-related cerebral hypoperfusion, inflammation, microhemorrhage, brain atrophy, and systemic atherosclerotic vascular disease. The mitigating role of oral anticoagulation in specific subgroups (eg, low stroke risk, short duration or silent AF, after successful AF ablation, or atrial cardiopathy) and the effect of rhythm versus rate control strategies remain unknown. Likewise, screening for AF (in cognitively normal or cognitively impaired patients) and screening for cognitive impairment in patients with AF are debated. The pathophysiology of dementia and therapeutic strategies to reduce cognitive impairment warrant further investigation in individuals with AF. Cognition should be evaluated in future AF studies and integrated with patient-specific outcome priorities and patient preferences. Further large-scale prospective studies and randomized trials are needed to establish whether AF is a risk factor for cognitive impairment, to investigate strategies to prevent dementia, and to determine whether screening for unknown AF followed by targeted therapy might prevent or reduce cognitive impairment and dementia.
A Method to Determine the Effect of the Individual Rotator Cuff Muscles to Dynamic Joint Stability of the Shoulder
Kim, Kyu Jung, Lee, Seok Beom, An, Kai , Morrey, B.F.

Mayo Clinic

Advances in Bioengineering | January 31, 2022 | Volume: No volume available | Issue: No issue available | Pages: 385-386

10.1115/imece1998-0186 Get It

Abstract The prevalence of rotator cuff disease among the elderly population and the greatest incidence of acute dislocations will continue to provide challenging patient management decisions. Stability of the shoulder is critical to successful upper extremity function. The GH joint is stabilized by passive capsuloligamentous restraints as well as by active dynamic stabilizers through concavity compression. The compression of the convex humeral head (HH) into the concave glenoid fossa (GF) counteracts against translational shear forces (Matsen et. al 1994). The major compressive load across the joint is provided by the action of the surrounding musculature, especially the rotator cuff. The muscles may generate both compressive and shear force components as well as moments. The purpose of this study is to describe a new testing methodology of how to estimate the contribution of individual rotator cuff muscles to the dynamic stability of the GH joint at a given joint position.
Excessive daytime sleepiness: an emerging marker of cardiovascular risk
Bock, Joshua M. , Covassin, Naima , Bock, Joshua , Somers, Virend, Somers, Virend K.

Mayo Clinic

Heart | January 31, 2022 | Volume: 108 | Issue: 22 | Pages: 1761-1766

10.1136/heartjnl-2021-319596 | PMID 35102000 Get It

Excessive daytime sleepiness (EDS) is classically viewed as a consequence of insufficient sleep or a symptom of sleep disorders. Epidemiological and clinical evidence have shown that patients reporting EDS in tandem with sleep disorders (e.g., obstructive sleep apnoea) are at greater cardiovascular risk than non-sleepy patients. While this may simply be attributable to EDS being present in patients with a more severe condition, treatment of sleep disorders does not consistently alleviate EDS, indicating potential aetiological differences. Moreover, not all patients with sleep disorders report EDS, and daytime sleepiness may be present even in the absence of any identifiable sleep disorder; thus, EDS could represent an independent pathophysiology. The purpose of this review is twofold: first, to highlight evidence that EDS increases cardiovascular risk in the presence of sleep disorders such as obstructive sleep apnoea, narcolepsy and idiopathic hypersomnia and second, to propose the notion that EDS may also increase cardiovascular risk in the absence of known sleep disorders, as supported by some epidemiological and observational data. We further highlight preliminary evidence suggesting systemic inflammation, which could be attributable to dysfunction of the gut microbiome and adipose tissue, as well as deleterious epigenetic changes, may promote EDS while also increasing cardiovascular risk; however, these pathways may be reciprocal and/or circumstantial. Additionally, gaps within the literature are noted followed by directions for future research.
Outcomes in post-acute sequelae of COVID-19 (PASC) at 6 months post-infection part 2: Psychological functioning
Whiteside, Douglas M. , Naini, Savana M. , Basso, Michael R. , Waldron, Eric J. , Holker, Erin , Porter, James N., Niskanen, Natalie, Melnik, Tanya E., Whiteside, Douglas , Taylor, Sarah E.

Mayo Clinic

The Clinical Neuropsychologist | January 31, 2022 | Volume: 36 | Issue: 4 | Pages: 829-847

10.1080/13854046.2022.2030411 | PMID 35098861 Get It

Ergonomic education in dermatology training: A survey
Deo, Neha , Carley, Sama K. , Mullen, Barbara , Vidal, Nahid Y. , Deo, Neha N

Mayo Clinic

Australasian Journal of Dermatology | January 31, 2022 | Volume: 63 | Issue: 2 | Pages: No page available

10.1111/ajd.13788 | PMID 35099069 Get It

Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer
Waks, Adrienne G. , Kim, Dewey, Jain, Esha , Snow, Craig, Kirkner, Gregory J., Rosenberg, Shoshana M., Oh, Coyin, Poorvu, Philip D., Ruddy, Kathryn J. , Tamimi, Rulla M. , Peppercorn, Jeffrey, Schapira, Lidia , Come, Steven E., Brachtel, Elena F. , Warner, Ellen, Collins, Laura C., Partridge, Ann H., Wagle, Nikhil, Borges, Virginia F , Brachtel, Elena F , Tamimi, Rulla M , Waks, Adrienne G , Kim, Dewey, Jain, Esha , Snow, Craig, Kirkner, Gregory J., Rosenberg, Shoshana M., Oh, Coyin, Poorvu, Philip D., Ruddy, Kathryn J , Peppercorn, Jeffrey, Schapira, Lidia , Come, Steven E., Warner, Ellen, Collins, Laura C., Partridge, Ann H., Wagle, Nikhil

Mayo Clinic

Clinical Cancer Research | January 31, 2022 | Volume: 28 | Issue: 11 | Pages: 2339-2348

10.1158/1078-0432.ccr-21-2572 | PMID 35101884 Get It

Abstract Purpose: Young age at breast cancer diagnosis correlates with unfavorable clinicopathologic features and worse outcomes compared with older women. Understanding biological differences between breast tumors in young versus older women may lead to better therapeutic approaches for younger patients. Experimental Design: We identified 100 patients ≤35 years old at nonmetastatic breast cancer diagnosis who participated in the prospective Young Women's Breast Cancer Study cohort. Tumors were assigned a surrogate intrinsic subtype based on receptor status and grade. Whole-exome sequencing of tumor and germline samples was performed. Genomic alterations were compared with older women (≥45 years old) in The Cancer Genome Atlas, according to intrinsic subtype. Results: Ninety-three tumors from 92 patients were successfully sequenced. Median age was 32.5 years; 52.7% of tumors were hormone receptor-positive/HER2-negative, 28.0% HER2-positive, and 16.1% triple-negative. Comparison of young to older women (median age 61 years) with luminal A tumors (N = 28 young women) revealed three significant differences: PIK3CA alterations were more common in older patients, whereas GATA3 and ARID1A alterations were more common in young patients. No significant genomic differences were found comparing age groups in other intrinsic subtypes. Twenty-two patients (23.9%) in the Young Women's Study cohort carried a pathogenic germline variant, most commonly (13 patients, 14.1%) in BRCA1/2. Conclusions: Somatic alterations in three genes (PIK3CA, GATA3, and ARID1A) occur at different frequencies in young versus older women with luminal A breast cancer. Additional investigation of these genes and associated pathways could delineate biological susceptibilities and improve treatment options for young patients with breast cancer. See related commentary by Yehia and Eng, p. 2209
Insulin Delivery and Glucose Variability Throughout the Menstrual Cycle on Closed Loop Control for Women with Type 1 Diabetes
O’Malley, Grenye , Raghinaru, Dan, Kudva, Yogish C. , Laffel, Lori M. , Pinsker, Jordan E. , Lum, John W. , Brown, Sue A. , Anderson, Stacey M. , Emory, Emma, Voelmle, Mary, Conshafter, Katie, Morris, Kim, Gondor-Fredrick, Linda, Mitchell, Harry, Calvo, Kayla, Wakeman, Christian, Breton, Marc D. , Ambler-Osborn, Louise, Flint, Emily, Kim, Kenny, Roethke, Lindsay, Church, Mei Mei , André, Camille , Piper, Molly, Lam, David W. , Levister, Camilla, Ogyaadu, Selassie, Lovett, Jessica, Simha, Vinaya , Dadlani, Vikash, McCrady-Spitzer, Shelly , Reid, Corey, Forlenza, Gregory P. , Slover, Robert H., Jost, Emily , Berget, Cari , Towers, Lindsey, Rossick-Solis, Alex, Ekhlaspour, Laya , Jacobson, Tali, Town, Marissa, Tabatabai, Ideen , Keller, Jordan, Salas, Evalina, Dassau, Eyal , Passman, Samantha, Campos, Tiffany, Kollman, Craig, Murphy, Carlos, Patibandla, Nandan, Borgman, Sarah, Arreaza-Rubín, Guillermo , Eggerman, Thomas L., Green, Neal, Reznik, Yves , Janicek, Robert, Gabrielson, Deanna, Belle, Steven H., Castle, Jessica R. , Legault, Laurent , Wysham, Carol , Kudva, Yogish C. , Laffel, Lori M , Pinsker, Jordan E , Lum, John , Forlenza, Gregory P , Levy, Carol J. , Kovatchev, Boris , Oliveri, Mary Clancy , Isganaitis, Elvira , Kumari, Kanchan, Wadwa, R Paul , Alonso, G. Todd , Messer, Laurel H , Buckingham, Bruce A. , Doyle, Francis J. , Beck, Roy W. , Kollman, Craig , Renard, Eric , Cobelli, Claudio , Green, Jennifer Greif , Willi, Steven Matthew

Mayo Clinic

Diabetes Technology & Therapeutics | January 31, 2022 | Volume: 24 | Issue: 5 | Pages: 357-361

10.1089/dia.2021.0431 | PMID 35099294 Get It

Objective: To analyze insulin delivery and glycemic metrics throughout the menstrual cycle for women with type 1 diabetes using closed loop control (CLC) insulin delivery. Methods: Menstruating women using a CLC system in a clinical trial were invited to record their menstrual cycles through a cycle-tracking application. Sixteen participants provided data for this secondary analysis over three or more complete cycles. Insulin delivery and continuous glucose monitoring (CGM) data were analyzed in relation to reported cycle phases. Results: Insulin delivery and CGM metrics remained consistent during cycle phases. Intraparticipant variability of CGM metrics and weight-based insulin delivery did not change through cycle phases. Conclusions: For this sample of menstruating women with type 1 diabetes using a CLC system, insulin delivery and glycemic metrics remained stable throughout menstrual cycle phases. Additional studies in this population are needed, particularly among women who report variable glycemic control during their cycles. Trial Registration: NCT03591354.